Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.


September 28, 2023
PresentationAV-380

CCS 2023: A phase 1b dose escalation study of AV-380 in combination with standard of care chemotherapy in metastatic cancer patients with cachexia and elevated GDF-15 levels

July 6, 2023
PublicationTivozanib

Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma (TIVO-3): A Phase 3, Multicentre, Randomised, Controlled, Open-Label Study

Authors: Brian I. Rini, Sumanta K. Pal, Bernard J. Escudier, Michael B. Atkins, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael N. Needle, David F. McDermott. Request for Reprint of The Lancet Oncology TIVO-3 Manuscript.

June 14, 2023
PublicationTivozanib

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial

Authors: Pedro C. Barata, Alexander Chehrazi-Raffle, Kimberly D. Allman, Aviva Asnis-Alibozek, Vijay Kasturi, Sumanta K. Pal. Click here for link to article.

March 28, 2023
PublicationFiclatuzumab

Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer

Authors: Julie E. Bauman, Nabil F. Saba, Denise Roe, Jessica R. Bauman, John Kaczmar, Aarti Bhatia, Jameel Muzaffar, Ricklie Julian, Steven Wang, Shethal Bearelly, Audrey Baker, Conor Steuer, Anshu Giri, Barbara Burtness, Sara Centuori, Carlos Caulin, Robert Klein, Kathylynn Saboda, Stefanie Obara, Christine H. Chung. Click here for link to article.

February 16, 2023
PresentationTivozanib

ASCO GU 2023: Estimated cost of adverse event management for patients with metastatic renal cell carcinoma treated with VEGFR TKI

January 19, 2023
PresentationTivozanib

ASCO GI 2023: Final Results of a Phase 1b/2 Study of Tivozanib in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma in Both Previously Untreated Patients and Patients Progressing on Atezolizumab and Bevacizumab